

Jaya Chakravarty

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2315295/jaya-chakravarty-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50
papers

2,158
citations

21
h-index

46
g-index

50
ext. papers

2,487
ext. citations

6.1
avg. IF

5.3
L-index

#	Paper	IF	Citations
50	Single-dose liposomal amphotericin B for visceral leishmaniasis in India. <i>New England Journal of Medicine</i> , 2010 , 362, 504-12	59.2	299
49	Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. <i>Lancet, The</i> , 2011 , 377, 477-86	40	245
48	Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. <i>Clinical Infectious Diseases</i> , 2012 , 55, 543-50	11.6	198
47	Leishmaniasis: an update of current pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 53-63	4	183
46	An update on pharmacotherapy for leishmaniasis. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 237-52	4	171
45	Drug resistance in leishmaniasis. <i>Journal of Global Infectious Diseases</i> , 2010 , 2, 167-76	2.8	170
44	A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. <i>Vaccine</i> , 2011 , 29, 3531-7	4.1	111
43	Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. <i>Infectious Diseases of Poverty</i> , 2016 , 5, 19	10.4	100
42	Paromomycin in the treatment of leishmaniasis. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 787-94	5.9	66
41	Current and emerging medications for the treatment of leishmaniasis. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1251-1265	4	63
40	Investigational drugs for visceral leishmaniasis. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 43-59	5.9	38
39	Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. <i>Clinical Infectious Diseases</i> , 2009 , 49, 914-8	11.6	38
38	Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. <i>Tropical Medicine and International Health</i> , 2013 , 18, 96-100	2.3	37
37	Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015 , 92, 513-7	3.2	34
36	Quantitative PCR in epidemiology for early detection of visceral leishmaniasis cases in India. <i>PLoS Neglected Tropical Diseases</i> , 2014 , 8, e3366	4.8	33
35	Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence. <i>Expert Review of Anti-Infective Therapy</i> , 2018 , 16, 805-812	5.5	30
34	Determinants for progression from asymptomatic infection to symptomatic visceral leishmaniasis: A cohort study. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007216	4.8	28

33	Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. <i>Scientific World Journal, The</i> , 2015 , 2015, 414378	2.2	27
32	Ambisome plus miltefosine for Indian patients with kala-azar. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2011 , 105, 115-7	2	26
31	Outcome of patients on second line antiretroviral therapy under programmatic condition in India. <i>BMC Infectious Diseases</i> , 2015 , 15, 517	4	23
30	Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. <i>Cell Reports</i> , 2020 , 30, 2512-2525.e9	10.6	21
29	Leishmaniasis: treatment, drug resistance and emerging therapies. <i>Expert Opinion on Orphan Drugs</i> , 2019 , 7, 1-10	1.1	21
28	Recent advances in the diagnosis and treatment of kala-azar. <i>The National Medical Journal of India</i> , 2012 , 25, 85-9	0.4	21
27	Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. <i>Lancet Microbe, The</i> , 2021 , 2, e23-e31	22.2	19
26	Prevalence of human papillomavirus infection & cervical abnormalities in HIV-positive women in eastern India. <i>Indian Journal of Medical Research</i> , 2016 , 143, 79-86	2.9	18
25	Meta-taxonomic analysis of prokaryotic and eukaryotic gut flora in stool samples from visceral leishmaniasis cases and endemic controls in Bihar State India. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007444	4.8	16
24	Determinants of survival in adult HIV patients on antiretroviral therapy in Eastern Uttar Pradesh: a prospective study. <i>Indian Journal of Medical Research</i> , 2014 , 140, 491-500	2.9	14
23	Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population-based with health facility-reported data. <i>PLoS Neglected Tropical Diseases</i> , 2020 , 14, e0007995	4.8	12
22	Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007673	4.8	11
21	Evaluation of rk39 immunochromatographic test with urine for diagnosis of visceral leishmaniasis. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2011 , 105, 537-9	2	10
20	Epitope-Binding Characteristics for Risk versus Protective DRB1 Alleles for Visceral Leishmaniasis. <i>Journal of Immunology</i> , 2018 , 200, 2727-2737	5.3	9
19	Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis. <i>ISRN Parasitology</i> , 2014 , 2014, 548010		8
18	Novel Antigen Detection Assay to Monitor Therapeutic Efficacy of Visceral Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016 , 95, 800-802	3.2	8
17	Human Papillomavirus Genome based Detection and Typing: A Holistic Molecular Approach. <i>Current Molecular Medicine</i> , 2019 , 19, 237-246	2.5	6
16	Why do Patients in Pre-Anti Retroviral Therapy (ART) Care Default: A Cross-Sectional Study. <i>Indian Journal of Community Medicine</i> , 2016 , 41, 241-4	0.8	6

15	Interleukin 2 is an Upstream Regulator of CD4+ T Cells From Visceral Leishmaniasis Patients With Therapeutic Potential. <i>Journal of Infectious Diseases</i> , 2019 , 220, 163-173	7	5
14	Clinical Abacavir Hypersensitivity Reaction among Children in India. <i>Indian Journal of Pediatrics</i> , 2016 , 83, 855-8	3	5
13	Association of interleukin-18 gene polymorphism with susceptibility to visceral leishmaniasis in endemic area of Bihar, an Indian population. <i>Scientific World Journal, The</i> , 2014 , 2014, 852104	2.2	5
12	Effectiveness of Single-Dose Liposomal Amphotericin B in Visceral Leishmaniasis in Bihar. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019 , 101, 795-798	3.2	5
11	Study the drug adherence and possible factor influencing drug adherence in HIV/AIDS patients in north eastern part of India. <i>Journal of Education and Health Promotion</i> , 2014 , 3, 31	1.4	3
10	Cloning, Expression and Purification of Specific Antigen for Serodiagnosis of Visceral Leishmaniasis. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2013 , 4, 1000141	2	3
9	Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1463-1473	6.2	3
8	Suppression of host PTEN gene expression for Leishmania donovani survival in Indian visceral leishmaniasis. <i>Microbes and Infection</i> , 2016 , 18, 369-72	9.3	2
7	Anti-Interleukin-10 Unleashes Transcriptional Response to Leishmanial Antigens in Visceral Leishmaniasis Patients. <i>Journal of Infectious Diseases</i> , 2021 , 223, 517-521	7	2
6	Human papillomavirus infection & anal cytological abnormalities in HIV-positive men in eastern India. <i>BMC Infectious Diseases</i> , 2018 , 18, 692	4	2
5	Factors affecting disclosure of HIV-positive serostatus among people living with HIV/AIDS attending an antiretroviral therapy center of Eastern India. <i>Indian Journal of Public Health</i> , 2020 , 64, 4-10 ^{1.8}		1
4	The utility of banana peel extract agar in the presumptive identification of Cryptococcus neoformans. <i>Journal of Microbiological Methods</i> , 2020 , 177, 106046	2.8	1
3	Uttar Pradesh Association of Physicians of India Position Statement: Tobacco Use and Metabolic Syndrome. <i>Journal of the Association of Physicians of India, The</i> , 2017 , 65, 66-72	0.4	1
2	An Unusual Presentation of Post kala-azar Dermal Leishmaniasis. <i>Indian Dermatology Online Journal</i> , 2020 , 11, 269-271	0.9	
1	Clinical and Biochemical Profile in Patients with Rheumatoid Arthritis with Special Reference to Insulin Resistance. <i>Journal of the Association of Physicians of India, The</i> , 2020 , 68, 71	0.4	